C-type natriuretic peptide analog treatment of craniosynostosis in a Crouzon syndrome mouse model

Activating mutations of fibroblast growth factor receptors (FGFRs) are a major cause of skeletal dysplasias, and thus they are potential targets for pharmaceutical intervention. BMN 111, a C-type natriuretic peptide analog, inhibits FGFR signaling at the level of the RAF1 kinase through natriuretic...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmes, Greg, Zhang, Lening, Rivera, Joshua, Murphy, Ryan, Assouline, Claudia, Sullivan, Lorraine, Oppeneer, Todd, Jabs, Ethylin Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062116/
https://www.ncbi.nlm.nih.gov/pubmed/30048539
http://dx.doi.org/10.1371/journal.pone.0201492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062116/
https://www.ncbi.nlm.nih.gov/pubmed/30048539
http://dx.doi.org/10.1371/journal.pone.0201492

Ejemplares similares